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The cost-effectiveness of hormone replacement therapy (HRT) based on a societal perspective is reassessed 
based on new medical evidence found in the Women’s Health Initiative (WHI). Within a model framework using 
an individual state transition model the cost-effectiveness of 50-60 year old women with menopausal symptoms 
is assessed in Sweden. The Markov model has a 50 year time horizon divided into a cycle length of 1 year. The 
model consists of the following disease states: Coronary Heart Disease (CHD), Stroke, Venous thromboembolic 
events, breast cancer, colorectal cancer, hip fracture, vertebral fracture and wrist fracture. An intervention is 
modelled by its impact on the disease risks during and after the cessation of therapy. The model calculates costs 
and quality adjusted life years (QALYs) with and without intervention. The resulting cost per gained QALY is 
compared to the value of a gained QALY, which is set to SEK 600 000. The model requires data on clinical 
effects, risks, mortality rates, quality of life weights and costs valid for Sweden. The cost-effectiveness ratios are 
estimated at about SEK 10 000, which is far below the value of a gained QALY. Conditional on that HRT 
increases the quality of life weight more than 0.013 the therapy is cost-effective. In conclusion, given the new 
evidence in WHI, there is still a high probability that HRT is a cost-effective strategy for women with 
menopausal symptoms. 
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1 INTRODUCTION 
Women in the industrialised part of the world are today living more than one third of their life 
after menopause. For example, in Sweden about 1.7 million women are above the age of 50, 
which corresponds to 19% of the population. The women’s health problem around the 
menopause, when the oestrogen production naturally decreases implies costs for society both 
in terms of quality of life losses but also in terms of costs arising within and outside the health 
care system. At menopause, which occurs on the average at age 51, about 75% of women 
experience menopausal symptoms such as hot flushes, night sweats and atrophy-related 
symptoms of the urogenital tract [1]. 10% of women suffer from symptoms more than 15 
years after the menopause. The effect of menopausal symptoms on quality of life may be 
substantial, which is shown in e.g. Daly et al. [2] and Zethraeus et al. [3]. In Sweden the costs 
for estrogens (estrogens, progestins and combination drugs) has increased from 370 to 500 
million SEK during the period 1995-2000. Restricting the sales in the year 2000 to women 
above the age of 45 years and with menopausal symptoms the sales are estimated at 300 – 400 
million SEK. Also, if costs for physician visits are added the total intervention cost of HRT 
amount to 600 – 700 million SEK in the year 2000 [1].
5  
 
The use of hormone replacement therapy (HRT) mitigates or eliminates menopausal 
symptoms and leads to a major improvement in quality of life for women with menopausal 
symptoms [2, 3]. HRT also offers protection against osteoporosis and related fractures and 
was previously believed to offer a cardio protective effect as shown in observational studies 
[4]. However, recent randomised studies do not show any reduction in cardiovascular events 
neither in secondary nor in primary prevention [5-7]. Evidence of the effect of HRT on breast 
cancer has been inconclusive, but now the general belief is that the risk of breast cancer 
increases [1, 4, 6-11]. However, for hysterectomised women on oestrogen only therapy the 
Women’s Health Initiative (WHI) study [7] shows a decreased risk of breast cancer. Results 
based on the WHI [6] show that HRT also changes the risk of colorectal cancer, venous 
thromboembolic events (VTE) and stroke. For non-hysterectomised women taking estrogens 
only, an increased risk of endometrial cancer is evident. The increased risk of endometrial 
cancer is eliminated by the addition of a progestin [1, 6]. Combining oestrogen with a 
                                                           
5 A distinction can be made between HRT regimes for women with a hysterectomy and for women with an intact 
uterus. Women with a hysterectomy are given oestrogen only therapy and in Sweden (2001) the mean annual 
drug cost was estimated at SEK 900 for this patient group. Women with an intact uterus is treated with a 
combination of oestrogen and progestin, and the mean annual drug cost for this patient group in Sweden in 2001   2
progestin may induce uterine bleedings; however, such bleedings may reduce or vanish if a 
combined HRT is continuously applied although break through bleeding often occurs in the 
first few months [1]. Today oestrogen only therapy is given only to women with a 
hysterectomy while women with an intact uterus are given oestrogen combined with a 
progestin to eliminate the endometrial cancer risk. 
 
Cost-effectiveness analysis (CEA) is a method for assessing costs and benefits of alternative 
ways of allocating resources to assist decisions aiming at improving efficiency. An efficient 
allocation of resources implies that no further health gains can be achieved by allocating 
resources differently. CEA is based on maximising health effects subject to a cost constraint, 
where costs are measured in monetary units and health effects in non-monetary units such as 
life years or quality adjusted life years (QALYs). QALYs are constructed by adjusting life 
years for the quality of life in which they are spent. To achieve this, the number of years in a 
health state is multiplied by a quality weight between 0 (dead) and 1 (full health). To be 
consistent with economic theory and to avoid suboptimisations a societal perspective should 
be carried out, which means that all costs and benefits are incorporated in the analysis no 
matter who pays the costs or receive the benefits. This has the consequence that e.g. costs in 
added years of life should be included [12]. To determine whether a treatment is cost-effective 
compared to an alternative the cost per gained unit of effectiveness (e.g. cost per gained 
QALY) must be compared with the willingness to pay (WTP) for a gained unit of 
effectiveness (e.g. the value gained QALY). If the price per unit increase in effectiveness 
exceeds the cost the programme is cost-effective. Without the information about the price per 
unit increase in effectiveness the CEA gives no information on whether a program is cost-
effective or not, unless it is sorted out as a dominated alternative (e.g. the program has higher 
costs and lower effectiveness). The value of a gained QALY is usually stated to be about SEK 
500 000 – 600 000 (US$ 50 000-60 000) [13, 14]. In this paper we use a value of SEK 600 
000 per QALY gained, which also can be derived from the value that the Swedish road 
authorities put on a statistical life.
6 To assess the cost-effectiveness of HRT the costs of the 
intervention costs must be related to the gain in quality of life from symptom relief and to the 
                                                                                                                                                                                     
was estimated at 1200. Different oestrogen and progestin combination regimes exist. The group variation in 
mean annual drug cost is however small varying between SEK 1200 – 1300. 
6 The Swedish road authority states that the WTP per life saved is equal to SEK 16.3 million (2001 prices). 16.3 
is divided by 1.53 to take account of crowding out effects of public investments. Life-years lost is equal to 20.4 
with 3% discounting and 17.3 QALYs lost with a QALY weight of 0.85. WTP per QALY gained = 16 300 
000/(1.53×17.3) = 600 000.   3
cost and health effect consequences of HRT due to changes in disease risks. If the value of the 
gain in effectiveness exceeds the increase in costs HRT is defined as cost-effective.  
 
Cost-effectiveness information is recommended or even required as a base for discussions 
with reimbursement authorities in different countries. For example, the Swedish 
pharmaceutical benefits board (LFN) clearly states that cost-effectiveness information is 
crucial when deciding whether to reimburse a new drug or whether to keep an existing drug 
on the benefits scheme. Cost-effectiveness information is also of importance for the National 
Institute for Clinical Evidence (NICE) when providing national guidance on treatments and 
care in the National Health Service (NHS) in England and Wales.  
 
To assess the cost-effectiveness of HRT modelling is required [15, 16]
7, which is also 
confirmed in previous cost-effectiveness studies [17-30]. Modelling is necessary because 
clinical trials cannot provide all the information that is needed for the economic evaluation, 
which requires cost and effectiveness information in a long run perspective. There are several 
types of modelling alternatives, e.g. decision tree models, Markov models, and discrete event 
models. Usually a so called state transition Markov model is used, which is characterised by a 
time horizon divided into equal increments of time called Markov cycles, health states and 
transition probabilities, which reallocates a hypothetical population between disease states 
e.g. once a year.  
 
All the cost-effectiveness studies from 1990 and onwards assumes that HRT decreases the 
risk of coronary heart disease, which was reflected in many observational studies at that time. 
Only a few of the cost-effectiveness studies are based on a societal perspective [17, 28, 29], 
which means that e.g. costs in added years of life are excluded from the analysis. Previous 
economic evaluation studies usually suggest that HRT is cost-effective for the treatment of 
menopausal symptoms [15, 28]. These economic evaluation studies are all based on medical 
evidence available before the WHI studies, which motivates a reassessment of the cost-
effectiveness of HRT based on the new evidence [6, 7]. The WHI is the first randomised, 
primary prevention study that investigates the effects of HRT on women with and without a 
hysterectomy. The main new finding in these studies is that HRT does not decrease the risk of 
                                                           
7 In Kim and Kwok 2003 the purpose was to estimate quality adjusted life expectancy with and without HRT for 
women with menopausal symptoms based on the findings in the WHI study (2002). The study is not a cost-
effectiveness study because it did not include any costs. They conclude that combination HRT compared to no 
therapy decrease life expectancy but increases quality adjusted life expectancy.   4
coronary heart disease, which has been assumed in previous cost-effectiveness analysis. A 
new finding is also that the mid-point estimate for breast cancer showed a reduction in 
hysterectomised women. This infers that it is the progestin component of HRT that may 
increase the risk of breast cancer. 
 
The purpose of the paper is to assess the cost-effectiveness of HRT for an average population 
of Swedish women with menopausal symptoms. The cost-effectiveness analysis is carried out 
based on a societal perspective and on the clinical findings in the WHI studies [6, 7]. The 
cost-effectiveness of HRT is calculated in 6 independent patient groups dependent on age (50, 
55 or 60 years) and uterus status (intact uterus or hysterectomised). Women with an intact 
uterus are supposed to be given combined therapy while hysterectomised women are 
supposed to be given oestrogen only therapy. In particular the following questions are 
investigated: Is it still cost-effective to use HRT for women with menopausal symptoms, 
given the new information in WHI? What is the minimum gain in quality of life that is 
required just to make the HRT cost-effective for women with menopausal symptoms? For 
each group, extensive one-way sensitivity analysis is carried out where e.g. the effects of 
HRT, remaining effects of HRT, size of the quality of life improvement, treatment duration 
and intervention cost is varied. 
 
The paper unfolds as follows: Section 2 introduces the model and defines the design and 
structure of the model. Section 3 specifies the data required for the model valid for Sweden. 
Section 4 presents the cost-effectiveness results based on the model described in Section 2 
and data presented in Section 3. Finally, section 5 concludes the paper. 
 
2 MODEL 
The cost-effectiveness model used in this study is based on a previously developed model [17, 
28, 29]. The model used has gone through some alteration compared to older versions. To 
capture all relevant effects of HRT found in the WHI the following disease states had to be 
included in the model: Coronary Heart Disease (CHD), Stroke, Venous thromboembolic 
events (VTE),  breast cancer, colorectal cancer, hip fracture, vertebral fracture and wrist 
fracture.  
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The preceding model versions have not considered stroke, colorectal cancer and VTE. The 
previous model that was based on Markov cohort methodology explicitly included the long-
term effects of diseases as health states, in all, the model comprised 14 health states. 
Continuing on the same model structure when including the new diseases would lead to a 
model with more than 20 health states. The larger a model is the less transparent it becomes. 
Also, by having too many health states with competing risks and restrictions on the transitions 
paths for having multiple diseases (e.g. not possible to have further disease events after 
having a CHD event) there is a potential risk of underestimating the risk of diseases in the 
model simulations, which might have an impact on the cost-effectiveness results. One way to 
solve this is to introduce individual based simulations instead of Markov cohort simulation. 
Instead of letting a patient cohort be distributed according to the given transition probabilities 
at the same time it is possible to let patients individually pass through the model, giving 
different transition paths for each patient. With this simulation method (sometimes-called first 
order simulation) it is possible to track the patient’s transition history, i.e. how and when 
certain events occurred throughout the simulation. One of the assumptions in Markov 
modelling is that no memory is allowed. Therefore this type of simulation method is better to 
be called an individual state transition based model than a Markov based model. The 
advantage with an individual state transition approach is that by keeping track of the patient 
disease history it is possible to reduce the number of health states by only implicitly model the 
long term (beyond the first year after the disease event) costs and effects of diseases. One 
disadvantage is that the simulations are more time consuming because by evaluating only one 
patient at a time, instead of the whole group as in Markov cohort simulation, there will be 
random variation in individual outcomes (called first-order uncertainty). To achieve stable 
results a large number of trials (a trial is one individual going through the model) have to be 
carried out. In order to use the most transparent model structure and avoid underestimating 
the number of disease events we chose the individual state transition approach. The final 
structure of the model that was used is shown in Figure 1. The arrows show all the allowed 
transitions in the model. There is always a possibility of dying or stay in the same health state, 
however, these arrows are excluded to simplify the figure. CHD consists of three different 
health states: acute myocardial infarction (AMI), angina pectoris and coronary insufficiency. 
The fracture-state consists of a hip fracture, vertebral fracture and a wrist fracture state 
(Figure 1 in here). 
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A patient starts a model simulation in the Well/No event state and passes through the model in 
yearly cycles between the different health states until 100 years of age or dead. Through the 
simulation the number and time of events for each patient is recorded. In each cycle it is 
possible to incur any disease event. The transitions are approximated to occur in the middle of 
each cycle, i.e. the model is half-cycle corrected.  
 
The main output from the model is costs and quality adjusted life years (QALYs), which 
allows for the computation of the incremental cost-effectiveness ratio of different treatment 
alternatives, e.g. using HRT compared to not using HRT. Some of the diseases have related 
costs and effects that stretch longer than one year. These could be accounted for by the 
memory functionality. In each cycle the model evaluates whether the patient have had any 
prior events and if they are related to any long term consequences (in costs and quality of 
life). If so, these consequences are accounted for when costs and quality of life is calculated. 
If the patient have had more than one disease event, then only the disease, which is related to 
the highest cost and quality of life reduction is used. The reason is that there are no available 
data on the cost and effect interrelationship between the diseases included in the model.  
 
An intervention is modelled by its impact on the disease risks during therapy and possible 
also after the cessation of therapy, which is a so-called remaining effect during an offset time 
period. In Figure 2, an example on how the effect of HRT on the risk of a disease can be 
modelled is shown. E.g to achieve a 40% decrease in the risk of fracture the base case risk of 
fracture (without intervention) is multiplied by 0.6 during the intervention period, which is set 
to 5 years. If there is a remaining effect of HRT on the fracture risk after the treatment period 
this is modelled as a linearly decline in the effect for a given “offset time” period. In Figure 2 
the remaining effect has vanished 5 years after the cessation of therapy. The model is flexible 
and allows for different assumptions of risk changes, lengths of treatment and offset time 
periods (Figure 2 in here).  
 
3 DATA 
The data for the model are based on available evidence for risks, mortality rates, quality of 
life weights and costs valid for Sweden. The inclusion of costs is based on a societal 
perspective including intervention costs, disease related costs and costs in added years of life. 
Cost and quality of life data are to a major extent based on empirical studies. Data on disease   7
risks and mortality rates are obtained from different national registers and epidemiological 
studies. All the data used in the model are presented in the Appendix (Tables A1 – A24). 
 
3.1  The effect of HRT 
The effects of HRT on disease risks during therapy are taken from the WHI studies [6, 7]. 
WHI focuses on defining the benefits and risks of different strategies that could potentially 
reduce the risk of e.g. heart disease and breast cancer. Both women with an intact uterus 
(treated with estrogens combined with progestins) and women hysterectomised (treated with 
estrogens alone) are followed. 
 
In the base case assumption a remaining effect of five years is assumed for fractures. There is 
a great deal of evidence that the offset of effect on the skeleton after stopping HRT is slow 
[31]. Thus, when HRT is stopped, some skeletal benefits continue. No other remaining effects 
are assumed to exist. In the case of breast cancer, the million women study [11] and other 
studies indicate that the risk is more or less immediately reversible once treatment is stopped. 
The same is also true for cardiovascular risk. 
 
In WHI [6] the objective was to assess major health benefits and risks of the most commonly 
used combination therapy (estrogens combined with progestins) in the US. The study, with an 
average follow-up of 5.2 years, reported the following significant relative risks (RR): CHD 
(RR=1.29), Stroke (RR=1.41), VTE (RR=2.11), breast cancer (RR=1.26), colorectal cancer 
(RR=0.63), hip fracture (RR=0.66), vertebral fracture (RR=0.66) and other osteoporotic 
fracture (RR=0.77).  
 
In WHI [7] the effects of oestrogen only therapy in postmenopausal women with a 
hysterectomy was presented. The study, with an average follow-up of 6.8 years, reported the 
following relative risks (RR): CHD (RR=0.91), Stroke (RR=1.39), VTE (RR=1.33), breast 
cancer (RR=0.77), colorectal cancer (RR=1.08), hip fracture (RR=0.61), vertebral fracture 
(RR=0.62) and total osteoporotic fractures (RR=0.70). Oestrogen only therapy significantly 
increased the risk of stroke and significantly reduced the risk of hip, vertebral and other total 
osteoporotic fractures. The relative risk of HRT used in this study is summarised in Table A1. 
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3.2 Disease  risks 
The target patient groups in the analysis were assumed to be at the same risk of fracture as the 
general population. Age specific population risks of hip, vertebral and wrist fracture for 
Swedish females used in the model were derived from a population based study from Malmö 
[32] (Table A2). Risks were given in 5-year intervals up to the age of 89 years. Interpolation 
was used to obtain age-specific fractures risks. To estimate the risk above the age of 89, 
which were not given in the referred article, logistic regression was fitted to the observational 
data and extrapolated beyond the observed ages in the data. For each age group, the middle 
age of the 5-year interval was used in the regression.  
 
To estimate the age specific incidence of non-skeletal events that was included in the model 
(breast cancer, colorectal cancer, CHD, Stroke, VTE) data was extracted from the Swedish 
national inpatient register administered by Centre for Epidemiology at the National Board of 
Health and Welfare. It covers all public inpatient care since 1987 and covers the reasons for 
hospitalisation and procedures undertaken (by ICD code) as well as date of admission and 
discharge. Registration is mandatory and is administrated by the county councils. All female 
patients that were diagnosed with one of the defined events (see Table A3 for a definition of 
the disease events in terms of ICD-10 identification codes) anytime 1998-01-01 to 2001-12-
31 was identified. All these patients’ inpatient stays from 1997-01-01 were extracted from the 
register. Using these data combined with Swedish population [33] data for the corresponding 
years the age differentiated incidence could be calculated for the different disease events 
included in the model (Table A2). The incidence is the average risk of an event in the 
population. Only the patient’s first event each year was included in the risk calculation and no 
division in risk between patients with and without previous disease event was made because 
the prevalence of the disease events in the population was not available.  
 
3.3 Mortality  rates 
The age-specific annual mortality rates for the general population in Sweden are based on the 
years 1998-2001 (Table A4) [33]. To fit the model structure normal mortality rates had to be 
adjusted to not include the risk of dying from disease events included in the model [17]. This 
adjusted normal mortality was calculated as normal mortality multiplied by the share of all 
causes of death [34] that was not explained by CHD, stroke, breast cancer and colorectal 
cancer (Table A5). The adjusted mortality rate (Table A6) is slightly overestimated since the 
number of deaths related to fractures and VTE were not available. This leads to an   9
overestimation of the number of deaths in the target patient group. To see, whether this slight 
overestimation of deaths might have an impact on the cost-effectiveness the normal 
population mortality was down adjusted by 50% in a sensitivity analysis.   
 
Patients with hip fractures and clinical vertebral fractures have a higher mortality compared to 
the normal population [35-40]. In a study by Johnell et al. [41] age differentiated mortality the 
first and following years after a hip fracture was calculated (Table A7 and Table A9). Age 
differentiated mortality risks (first and following years) after clinical vertebral fractures was 
derived from Johnell et al. [41] (Table A10 and Table A12). A part of the excess mortality 
after fracture compared to normal mortality cannot entirely be ascribed the fracture event but 
also to other co morbid conditions [42]. In Parker and Anand [42] it was estimated that 33% 
of the deaths one year after hip fracture were totally unrelated to the hip fracture, 42% 
possibly related and 25% directly related. In another study on Swedish hip fracture patients 
only 17%- 32% of all deaths were found to be causally related to the fracture [43]. Kanis et al. 
[39] estimated that approximately 30% of the excess mortality after vertebral fracture was 
related to the fracture event. Along with these findings we assumed that 30% of the observed 
excess mortality after a hip or vertebral fracture could be associated to the fracture event. The 
adjusted mortality rates the first year after events are shown in Table A8 and Table A11. 
Wrist fracture was assumed not to be associated with any excess mortality [36, 41]. 
 
Mortality after breast cancer, colorectal cancer, CHD, Stroke and VTE was derived by linking 
the inpatient sample extracted from the inpatient register with the register for causes of death 
also monitored by the Centre for Epidemiology at the National Board of Health and Welfare. 
Data on death events were available up to 2001-12-31. The yearly mortality rates were 
estimated using parametric Weibull survival regression [44]. The Weibull distribution is 
suitable for modelling data with hazard rates that increase or decrease over time and allows 
for the estimation of probability of an event in different time intervals after the starting point, 
e.g. the probability of dying the third year after an event. These types of calculations are not 
possible with other non-parametric survival analysis methods (e.g. Kaplan-Meier functions). 
The cost-effectiveness model follows patients at yearly risks of different events over a longer 
time period. The Weibull survival regression was therefore the most appropriate survival 
function to use for the estimation of the yearly mortality risk based on the available data. 
Assume that the length of time an individual lives (T ≥ 0) follows a Weibull distribution. For   10
t, a particular value of T, the Weibull survivor S(t) and hazard function ) (t λ are defined 
according to:  
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where  p and γ are non-negative parameters to be estimated. When p = 1, the Weibull 
distribution reduces to the exponential with a constant hazard and if p > 1 (p < 1) the hazard is 
monotonically increasing (decreasing) in t. To introduce covariates in the model, γ  in (1,2) is 
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The estimated parameter values in the Weibull survivor and hazard functions are given in 
Table A13. To estimate the mortality risk (r) for a certain year (t=1,2,3 etc) after the event the 
following formula was used:  
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where the ratio between the survivor functions is equal to the hazard function integrated 
between t-1 and t. Table A14 to Table A20 show the estimated mortality risks, using the 
formula in (5), for the first year after CHD, stroke, VTE, breast cancer and colorectal cancer.  
 
In all the estimated functions the mortality rate decreases for each year that passes after the 
event (i.e. p < 1). The estimated mortality risk decreases with time after the event. In some 
instances, when many years has passed, it is actually possible that the mortality is estimated to   11
be lower than population mortality, which is not reasonable. To avoid this, the mortality rate 
was assumed not to be lower than the population mortality. That is, if the estimated mortality 
risk according to the Weibull regression model was lower than population mortality, the 
population mortality was used.  
 
The use of Weibull functions allow for a more detailed modelling of the mortality compared 
to previous model versions [17] , which have used one mortality rate the first year and one 
mortality rate for second and all the subsequent years after event. As long as the used 
mortality rate for the subsequent years after an event is a good measure of the average 
mortality for all subsequent years the two modelling approaches should not lead to any major 
differences in the cost-effectiveness estimations.  
 
 
3.4  Quality of life weights 
The estimation of the gain in quality of life from HRT is based on a Swedish empirical study 
[3]. The increase in the QALY weight due to HRT for women with mild symptoms was 0.18 
according to the TTO method. For women with severe symptoms, the QALY weight 
increased by 0.42 according to the TTO method. In the base case analysis we assume that the 
loss in quality of life is equal to 0.29 corresponding to an average woman with menopausal 
symptoms. E.g. to estimate the quality weight for an average woman with menopausal 
symptoms 0.29 is subtracted from the QALY weight for a healthy women. 
 
The impact on quality of life the first year after a fracture (hip, vertebral and wrist) was based 
on a study conducted at the orthopaedic department at the Malmö University Hospital in the 
south of Sweden [45]. Participating patients filled out a EuroQol-5D questionnaire 2 weeks, 6, 
9 and 12 months after the fracture event. Since the quality of life before fracture was not 
collected, quality of life values for the population [46] were used as proxies for the patient 
quality of life before fracture. Accounting for the gender distribution in the study sample the 
disutility the first year after fracture was calculated [47]. The quality of life in subsequent 
years after a hip fracture was assumed to be 90% of that of a healthy individual [48]. Wrist 
fracture was not assumed to be associated with any utility loss the second or the second and 
following years after fracture. A multi-centre multi-national study showed that the quality of 
life was reduced by approximately 9% when the clinical vertebral fracture may have occurred   12
at a previously unknown time [49]. Based on these findings, it was conservatively assumed 
that the loss of utility the second and following years for a clinical vertebral fracture was 0.05.  
 
The utility loss after CHD, based on previous studies [50-52], was assumed to be 0.1 for all 
years after disease event and for all ages. Data on the utility loss after breast cancer, colorectal 
cancer, stroke and VTE are scarce. As in Zethraeus et al. [17, 28, 29] we assumed the utility 
loss associated with breast cancer to be equal to the loss after CHD. The same utility loss was 
assumed for colorectal cancer and VTE. Age differentiated quality of life weights for all 
diseases are summarised in Table A21.   
 
3.5 Costs 
In the case of preventive programs, e.g. HRT, it is useful to make a distinction between 
intervention costs, morbidity costs and costs in added years of life. Intervention costs are 
inputs that go into a health care program and consist of direct costs (e.g. costs for drugs and 
physician visits) and indirect costs which depict production losses (or losses in leisure time) 
due to the treatment participation. Morbidity costs are resource consequences due to changes 
in morbidity (e.g. changes in fracture and breast cancer risks) and consist of direct and 
indirect costs caused by the disease. Costs in added life years are the resource consequences 
due to changes in mortality and are estimated as the change in consumption (medical and non-
medical) minus the change in production due to the change in mortality. All costs are 
expressed in the prices of 2003. When needed the costs were inflated using the Consumer 
Price Index from Statistics Sweden [34]. 
 
The annual intervention cost for women on combination therapy (with an intact uterus) is 
estimated at SEK 2 972. This consist of drug costs (SEK 1220 [1]), 1.5 physician visits per 
year at a price of SEK 1 168 per visit. The corresponding annual intervention cost for women 
on oestrogen only therapy (with a hysterectomy) is estimated at SEK 2 078. This consist of 
drug costs (SEK 910 [1]), 1 physician visit per year at a price of SEK 1 168.  
 
Costs of a fracture can be divided into acute costs, which occur the first year following the 
fracture, and long-term costs, which can persist several years after fracture or even for the 
remainder of the lifetime of the patient. Direct and indirect fracture costs in Sweden during 
the first year after a hip, clinical vertebral and wrist fracture were derived from Zethraeus et 
al. [45]. Hip fracture costs the second and following years were based on the assumption that   13
10% of all patients remain at a nursing home for the rest of their lives [48] at a weekly cost of  
1 486 SEK [53]. There are currently no empirical estimates on the fracture-related cost of 
vertebral and wrist fracture beyond the first year after fracture event in Sweden, therefore it 
was conservatively assumed that these fractures were associated with costs only the first year 
after fracture. Table A22 and Table A23 summarises the fracture-related costs that were used 
in the analysis.  
 
Direct and indirect costs related to CHD (AMI, coronary insufficiency and Angina pectoris) 
the first year and subsequent years after event and first year costs (direct and indirect) of 
stroke were based on estimates given in Zethraeus et al. [29]. Indirect costs related to breast 
cancer come from Liljegren et al. [54]. Direct costs associated to breast cancer, colorectal 
cancer and VTE were estimated from the patient sample extracted from the national inpatient 
register. Direct costs the second and following years after stroke, was also derived from this 
sample. The cost of the patient’s hospital stays was assessed using the Diagnosis Related 
Groups (DRG) costing system. To estimate the potential cost saving of avoiding an event the 
patients were used as his or her own control [55]. The costs related to an event were estimated 
as the difference 1 year after and 1 year before the event. Event related costs the second and 
following years were estimated as the difference the second year after event and 1 year before 
the event. Only patients with sufficient observation time, from incident date to end date 
(2001-12-31), were included in the calculations. That is at least 1 year for the estimation of 
first year costs and 2 years for estimation of costs the second year after event. Patients that 
died within the observation time were also included in the cost estimates. That is, for the first 
year cost estimates, all patients that died during the first year were included. For the cost 
estimates subsequent years patients that died the first year was excluded but patients that died 
during the second year were included. This is in line with the structure of the model. The 
starting incident event date was the first identified diagnoses each year. To be in concordance 
with the risk of events that was used in the model the costs were based on all female patients 
irrespective of inpatient history (i.e. patients with and without prior events). The calculated 
mean costs based on the inpatient sample are shown in Table A22. It should be noted that the 
inpatient cost estimates do not reflect the full potential direct cost savings because outpatient 
care and pharmaceutical costs based on prescriptions are not included. However, since such 
information is not available we made the conservative assumption of only including cost of 
inpatient care.  
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Costs in added years of life, defined as the difference between annual production and 
consumption in different age groups, are based on Ekman [56] (Table A24). The figures are 
adjusted to the price level of 2003 according to the consumer price index of Sweden [34]. 
 
4 RESULTS 
The results from the health effect, cost and cost-effectiveness results of a five-year HRT are 
presented in Tables 1-4. The calculations are based on the data described in section 3 above 
and assess the health and cost consequences of HRT for a 50-60 year old female population 
with average disease risk and menopausal symptoms. The results are separated for women 
with an intact uterus and for women with a hysterectomy. Women with an intact uterus are 
given a combination therapy while women with a hysterectomy are treated with oestrogen 
only therapy. 
 
4.1  Health effects and costs 
The health effect consequences of HRT in the different patient groups in terms of life years 
(LYs) and QALYs are presented in Table 1. HRT implies a loss in the expected number of 
life years for women with an intact uterus on combination therapy. The mean decrease in 
expected life years is between 0.04-0.05, which corresponds to 15-18 days. After discounting 
the mean decrease varies between 0.02 and 0.03 life years. HRT will increase the number of 
expected QALYs compared to no therapy in all the age groups. The increase in the number of 
QALYs (with and without discounting) is between 1.2 and 1.3. 
 
For women with a hysterectomy on oestrogen only therapy, HRT implies a gain in life 
expectancy, which amounts to 0.01-0.06, which corresponds to 4-22 days. After discounting 
the mean increase is between 0.006-0.03 years. HRT will increase the number of expected 
QALYs compared to no therapy in all the age groups. The increase in QALYs (with and 
without discounting) is estimated at between 1.2 and 1.3 (Table 1 in here). 
 
The cost consequences are shown in Table 2. The mean difference in costs in the different age 
groups is estimated at between 10 000 and 15 000 SEK. In older age groups the cost-level 
becomes higher. This is explained by that the value of production decreases, which implies 
that the costs of (consumption-production) will increase and result in a total higher costs 
(Table 2 in here).   15
 
4.2 Cost-effectiveness 
The cost-effectiveness results for women with an intact uterus are presented in Table 3. In the 
base case scenario the cost per gained QALY varies between SEK 9000 and 13 000 in the 
different age groups, which is below the defined threshold value of SEK 600 000. It is clear 
that the cost-effectiveness ratios are stable to all but one of the alternative scenarios specified 
in the sensitivity analysis. The results are only sensitive to whether the therapy has a positive 
effect on menopausal symptoms or not. If it is assumed that HRT does not increase quality of 
life, HRT is dominated by the no-therapy alternative, which means that the no-treatment 
alternative implies more QALYs and lower costs (Table 3 in here). 
 
The results for women with a hysterectomy are presented in Table 4. In the base case scenario 
the cost per gained QALY varies between SEK 8 000 for a 50-year aged women and SEK 
11 000 for a 60-year aged women, which is also below the defined threshold value of SEK 
600 000. The cost-effectiveness ratios are stable to all but one of the alternative scenarios 
specified in the sensitivity analysis. If it is assumed that HRT does not affect quality of life, 
this implies that the cost-effectiveness ratio exceeds the threshold value of SEK 600  000 
(above SEK 1 million at the ages 50 and 55). However, for a 60-year old woman the cost-
effectiveness ratio (SEK 500 000) is still below the threshold value (Table 4 in here). 
 
To investigate the effect that the elimination of menopausal symptoms has on cost-
effectiveness a threshold analysis was carried out. The purpose of the threshold analysis was 
to determine the minimum increase in quality of life that is required just to make the treatment 
cost-effective. The analysis showed that HRT is cost-effective for women with or without a 
hysterectomy (irrespective of age) if the gain in quality of life exceeds 0.013 units.  
 
5 CONCLUDING  REMARKS 
This study has re-examined the cost-effectiveness of HRT for an average Swedish female 
population with menopausal symptoms based on a societal perspective and new evidence 
presented in the WHI studies [6, 7]. The cost per gained QALY varies for 50-60 year old 
women between SEK 8 000 for women with a hysterectomy and SEK 13 000 for women with 
an intact uterus, which is far below the defined threshold value of SEK 600 000. The results 
show that the value of the positive effects for women with menopausal symptoms in terms of 
symptom relief clearly outweighs the negative effects of HRT. Given that HRT increases the   16
quality of life more than 0.013 units, HRT becomes cost-effective in all the studied patient 
groups. In one patientgroup, 60-year old hysterectomised women on oestrogen only therapy, 
HRT is cost-effective irrespectively of any symptom relief. The threshold value of 0.013 can 
be compared with empirical findings that shows that HRT on average increases quality of life 
with 0.29 and with 0.18 for women with mild menopausal symptoms, which clearly exceeds 
the required increase in quality of life that makes HRT cost-effective [2, 3]. Thus, given the 
new evidence in WHI, there is still a high probability that HRT is a cost-effective strategy for 
women with menopausal symptoms.  
 
The results in this report are similar to the findings presented in two recent published studies 
[16, 57] that assess the health effects of HRT based on the WHI [6]. The purpose of the study 
by Col et al. [57] was, by exploring the trade-off between symptomatic relief and risk of 
disease, to determine which women might benefit from HRT. In a Markov model they 
included the following health states: breast, colorectal, ovarian, and endometrial cancer, CHD, 
stroke, hip fracture and pulmonary embolism. A cohort of healthy women was analysed that 
each year could develop any one or a combination of the included diseases or die of other 
causes. The study purpose was to calculate the effects of HRT on life years and QALYs for 
50-year old menopausal women on a 2-year combination therapy. The utility scores were 
derived from the literature. It was assumed that HRT decreased the loss in quality by 80%. 
The quality of life with and without menopausal symptoms was based on a study by 
Zethraeus et al. [3] and Daly et al. [2]. The results showed that HRT was associated with 
losses in (undiscounted) expected survival but gains in QALYs. For an average 50-year old 
women a two-year HRT implied a loss in expected survival of 12 days, which can be 
compared with 15 days found in this report (or 4 days if assessing a treatment time of 2 
years). On the other hand HRT implied a gain in (undiscounted) QALYs for 50-year old 
women with a low risk of CHD and stroke estimated at 0.36 and 0.69 for women with mild 
and severe symptoms respectively. In our report the corresponding (undiscounted) gain in 
QALYs amounted to 1.26. The corresponding adjusted (undiscounted) gain in QALYs for a 
2-year treatment amounted to 0.42, which is very close to the results presented in Col et al. 
[57]. Col et al. [57] further showed in a threshold analysis that if the effect of HRT on 
menopausal symptoms for women with an average risk of CHD and stroke is equal to or 
exceeds 0.04 HRT will increase the number of (undiscounted) QALYs. This can be compared 
with the corresponding figure of 0.01 found in this report (for a treatment period of 2 years).  
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The findings in this report are also close to the results presented in Kim & Kwok [16]. The 
purpose of that study was to estimate quality-adjusted life expectancy with and without HRT 
for women with an intact uterus on combination therapy (based on the treatment in WHI [6]). 
The analysis is based on a Markov state transition including the following disease states: 
breast cancer, CHD, stroke pulmonary embolism, colon cancer, and hip fracture. Endometrial 
cancer was excluded, because HRT did not increase the risk of endometrial cancer in the WHI 
for women with an intact uterus on combination therapy. Three cohorts of 50-year old women 
with menopausal symptoms were analysed: The first cohort consisted of healthy women at 
low risk of breast cancer and CHD; the second cohort consisted of women with a high risk of 
osteoporosis; the third cohort consisted of women with high risk for adverse events. Each year 
the cohort was subject to risks of any or a combination of the included disease events. For 
each cohort no HRT, HRT for five years and HRT for 15 years were evaluated. The time 
horizon for the model was 20 years. The results were both undiscounted and discounted by a 
rate of 3%. The authors assumed a quality of life weight equal to 1 with HRT (and without 
menopausal symptoms) and then determined the required improvement in quality of life that 
was necessary to obtain an increase in QALYs with HRT. Menopausal symptoms were 
assumed to last the same length as the treatment duration. The results showed that a five-year 
HRT reduced the expected life length by 0.01 years using a 3% discount rate for women at 
low risk of breast cancer and CHD. This is very similar to the results found in this report, 
which shows a decrease in expected (discounted at 3%) life length of 0.02 years for 50-year 
old women with intact uterus on combination therapy. Kim and Kwok [16] finally showed 
that the required improvement in the quality of life to obtain an increase in the number of 
QALYs, equalled 0.004, which can be compared with 0.015 found in this report.  
 
A majority of previous cost-effectiveness studies (before the WHI) have based their 
estimations of the quality of life weights before and after HRT on assumptions, rather than 
based on empirical data [19, 21, 23, 27, 58]. E.g. Weinstein assumed that the loss of quality of 
life due to menopausal symptoms was 0.01. The first empirical study to estimate the quality 
of life weight related to menopausal symptoms was carried out in a British setting and 
indicated that the previous assumptions underestimated the negative effect of menopausal 
symptoms. Daly’s results showed that menopausal symptoms seem to have a much more 
severe impact on quality of life than assumed in analyses of cost-effectiveness, and that HRT 
causes a much greater improvement in quality of life than previously assumed. These findings 
were confirmed in a later Swedish study by Zethraeus et al. [3], which assessed the quality of   18
life before and after HRT for a group of Swedish women with menopausal symptoms. The 
results found in Zethraeus et al. [3] using the RS method are very similar to those of Daly et 
al. [2]. In Daly et al [2] the quality of life weight increased from 0.61 to 0.79 with HRT for 
women with mild symptoms and from 0.29 to 0.85 for women with severe symptoms, 
compared with increases from 0.60 to 0.86 for women with mild symptoms and 0.32 to 0.82 
for women with severe symptoms in Zethraeus et al. [3]. The results of both studies indicate 
that the effect of menopausal symptoms on the quality of life has been underestimated. It 
should be pointed out that the RS method tends to exaggerate the gain in quality of life 
compared to other methods [59, 60]. However, in Zethraeus et al. [3] the gain in the quality of 
life was also measured by the TTO method. The TTO method gives a significantly lower gain 
in quality of life than the RS. The increase in the quality of life weight of 0.18 for women 
with mild symptoms and 0.42 for women with severe symptoms are, however, clinically 
significant. This indicates that the gains in quality of life are much higher than previously 
assumed and also shows the importance of carrying out empirical studies on quality of life 
rather than making arbitrary assumptions. A limitation of the above empirical studies is that 
they include few patients and may not be representative of all women receiving HRT in 
Sweden and the UK and that the sub-groups may not be representative of all women with 
mild and severe menopausal symptoms in Sweden and the UK. The results of these studies 
therefore may not be general. To investigate the real effect of menopausal symptoms and 
HRT on the quality of life further randomised studies are required.  
 
The model used to estimate the cost-effectiveness with HRT is based on a previously model 
that has been well-validated and published in the literature [17, 28, 29]. The purpose of the 
model is to represent the current state of the art and to reflect the best knowledge available 
today. In line with this the model is filled with high quality cost, mortality, quality of life and 
risk data. The model also produces similar results on the health effect measures compared 
with the results found in two recent published studies [16, 57], which validates the findings in 
this report. Still some of the data in the model is based on assumptions. In particular there is a 
lack of empirical based quality of life estimates related to non-skeletal disease events. To take 
this into account extensive sensitivity analysis has been carried out, where the base case 
assumptions are changed. The results from the sensitivity analysis show that the conclusions 
are stable to variations in these variables.  
   19
It is not evident whether the results found in the WHI are valid for other populations e.g. 
women with high risk of fracture (osteoporotic women). The WHI focused on a healthy 
women population and the extent to which benefits on the skeletal system in individuals at 
high risk outweigh adverse effects requires re-examination in this context. Epidemiological 
information indicates that the baseline risk for breast cancer is approximately 30% lower in 
individuals with osteoporosis, possibly related to more marked gonadal hormone deficiency in 
individuals with low bone mineral density (and low body mass index). To investigate the 
cost-effectiveness of HRT in this population group and for other indications further clinical 
studies are requested which is a subject for future research.   20
REFERENCES 
 
1. SBU,  Behandling med östrogen - En evidensbaserad kunskapssammanställning, in SBU rapport Nr 
159. 2002, Statens beredning för medicinsk utvärdering (SBU): Stockholm. 
2.  Daly, E., A. Gray, D. Barlow, K. McPherson, M. Roche, and M. Vessey, Measuring the impact of 
menopausal symptoms on quality of life. Bmj, 1993. 307(6908): p. 836-40. 
3.  Zethraeus, N., M. Johannesson, P. Henriksson, and R.T. Strand, The impact of hormone replacement 
therapy on quality of life and willingness to pay. Br J Obstet Gynaecol, 1997. 104(10): p. 1191-5. 
4. SBU,  Behandling med östrogen, in SBU rapport Nr 131. 1996, Statens beredning för medicinsk 
utvärdering (SBU): Stockholm. 
5.  Hulley, S., D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff, Randomized 
trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal 
women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama, 1998. 
280(7): p. 605-13. 
6.  Rossouw, J.E., G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. 
Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, and J. Ockene, Risks and benefits 
of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's 
Health Initiative randomized controlled trial. Jama, 2002. 288(3): p. 321-33. 
7.  Anderson, G.L., M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, H. Black, D. Bonds, R. 
Brunner, R. Brzyski, B. Caan, R. Chlebowski, D. Curb, M. Gass, J. Hays, G. Heiss, S. Hendrix, B.V. 
Howard, J. Hsia, A. Hubbell, R. Jackson, K.C. Johnson, H. Judd, J.M. Kotchen, L. Kuller, A.Z. 
LaCroix, D. Lane, R.D. Langer, N. Lasser, C.E. Lewis, J. Manson, K. Margolis, J. Ockene, M.J. 
O'Sullivan, L. Phillips, R.L. Prentice, C. Ritenbaugh, J. Robbins, J.E. Rossouw, G. Sarto, M.L. 
Stefanick, L. Van Horn, J. Wactawski-Wende, R. Wallace, and S. Wassertheil-Smoller, Effects of 
conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health 
Initiative randomized controlled trial. Jama, 2004. 291(14): p. 1701-12. 
8.  Colditz, G.A., S.E. Hankinson, D.J. Hunter, W.C. Willett, J.E. Manson, M.J. Stampfer, C. Hennekens, 
B. Rosner, and F.E. Speizer, The use of estrogens and progestins and the risk of breast cancer in 
postmenopausal women. N Engl J Med, 1995. 332(24): p. 1589-93. 
9.  Stanford, J.L., N.S. Weiss, L.F. Voigt, J.R. Daling, L.A. Habel, and M.A. Rossing, Combined estrogen 
and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. 
Jama, 1995. 274(2): p. 137-42. 
10.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 
epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast 
cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet, 1997. 350(9084): p. 
1047-59. 
11. Beral,  V.,  Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 2003. 
362(9382): p. 419-27. 
12. Meltzer,  D.,  Accounting for future costs in medical cost-effectiveness analysis. J Health Econ, 1997. 
16(1): p. 33-64. 
13.  Hirth, R.A., M.E. Chernew, E. Miller, A.M. Fendrick, and W.G. Weissert, Willingness to pay for a 
quality-adjusted life year: in search of a standard.PG - 332-42. Med Decis Making, 2000. 20(3). 
14. Johannesson,  M.,  At what coronary risk level is it cost-effective to initiate cholesterol lowering drug 
treatment in primary prevention? Eur Heart J, 2001. 22(11): p. 919-25. 
15.  Zethraeus, N., W. Ben Sedrine, F. Caulin, S. Corcaud, H.J. Gathon, M. Haim, O. Johnell, B. Jonsson, 
J.A. Kanis, Y. Tsouderos, and J.Y. Reginster, Models for assessing the cost-effectiveness of the 
treatment and prevention of osteoporosis. Osteoporos Int, 2002. 13(11): p. 841-57. 
16.  Kim, C. and Y.S. Kwok, Decision analysis of hormone replacement therapy after the Women's Health 
Initiative. Am J Obstet Gynecol, 2003. 189(5): p. 1228-33. 
17.  Zethraeus, N., M. Johannesson, and B. Jonsson, A computer model to analyze the cost-effectiveness of 
hormone replacement therapy. Int J Technol Assess Health Care, 1999. 15(2): p. 352-65. 
18.  Tosteson, A.N. and M.C. Weinstein, Cost-effectiveness of hormone replacement therapy after the 
menopause. Baillieres Clin Obstet Gynaecol, 1991. 5(4): p. 943-59. 
19.  Tosteson, A.N., D.I. Rosenthal, L.J. Melton, 3rd, and M.C. Weinstein, Cost effectiveness of screening 
perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. 
Ann Intern Med, 1990. 113(8): p. 594-603. 
20. Weinstein,  M.C.  and A.N. Tosteson, Cost-effectiveness of hormone replacement. Ann N Y Acad Sci, 
1990. 592: p. 162-72; discussion 185-92.   21
21.  Weinstein, M.C. and I. Schiff, Cost-effectiveness of hormone replacement therapy in the menopause. 
Obstet Gynecol Surv, 1983. 38(8): p. 445-55. 
22.  Daly, E., M.P. Vessey, D. Barlow, A. Gray, K. McPherson, and M. Roche, Hormone replacement 
therapy in a risk-benefit perspective. Maturitas, 1996. 23(2): p. 247-59. 
23.  Daly, E., M. Roche, D. Barlow, A. Gray, K. McPherson, and M. Vessey, HRT: an analysis of benefits, 
risks and costs. Br Med Bull, 1992. 48(2): p. 368-400. 
24.  Armstrong, K., T.M. Chen, D. Albert, T.C. Randall, and J.S. Schwartz, Cost-effectiveness of raloxifene 
and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet 
Gynecol, 2001. 98(6): p. 996-1003. 
25. Tosteson,  A.N.,  Hormone replacement therapy: benefit, risk and cost considerations. J Clin Pharmacol, 
1994. 34(7): p. 719-22. 
26.  Geelhoed, E., A. Harris, and R. Prince, Cost-effectiveness analysis of hormone replacement therapy and 
lifestyle intervention for hip fracture. Aust J Public Health, 1994. 18(2): p. 153-60. 
27.  Cheung, A.P. and B.G. Wren, A cost-effectiveness analysis of hormone replacement therapy in the 
menopause. Med J Aust, 1992. 156(5): p. 312-6. 
28.  Zethraeus, N., M. Johanneson, and B. Jönsson, A computer model to analyse the cost effectiveness of 
hormone replacement therapy. EFI Research Paper, 1998. 6578(January). 
29.  Zethraeus, N., P. Lindgren, O. Johnell, and B. Jönsson, A computer model to analyse the cost 
effectiveness of hormone replacement therapy - a revised version. SSI/EFI Working Paper Series in 
Economics and Finance, at the Stockholm School of Economics, 2000. 368. 
30.  Effectiveness and Costs of osteoporosis screening and hormone replacement therapy: Vol. I: Cost-
effectiveness Analysis, Vol. II: Evidence on benefits, risks and costs. 1995, Office of Technology 
Assessment. US Government printing Office. 
31.  Bagger, Y.Z., L.B. Tanko, P. Alexandersen, H.B. Hansen, A. Mollgaard, P. Ravn, P. Qvist, J.A. Kanis, 
and C. Christiansen, Two to three years of hormone replacement treatment in healthy women have long-
term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone, 2004. 34(4): p. 
728-35. 
32.  Kanis, J.A., O. Johnell, A. Oden, I. Sembo, I. Redlund-Johnell, A. Dawson, C. De Laet, and B. Jonsson, 
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int, 2000. 11(8): p. 669-74. 
33.  Statistics Sweden. Sweden´s Statistical Databases. http://www.scb.se/eng/databaser/ssd.asp. 
34.  Statistics Sweden. Sweden´s Statistical Databases., in http://www.scb.se. 
35.  Cauley, J.A., D.E. Thompson, K.C. Ensrud, J.C. Scott, and D. Black, Risk of mortality following 
clinical fractures. Osteoporos Int, 2000. 11(7): p. 556-61. 
36.  Center, J.R., T.V. Nguyen, D. Schneider, P.N. Sambrook, and J.A. Eisman, Mortality after all major 
types of osteoporotic fracture in men and women: an observational study. Lancet, 1999. 353(9156): p. 
878-82. 
37.  Cooper, C., E.J. Atkinson, S.J. Jacobsen, W.M. O'Fallon, and L.J. Melton, 3rd, Population-based study 
of survival after osteoporotic fractures. Am J Epidemiol, 1993. 137(9): p. 1001-5. 
38.  Jalava, T., S. Sarna, L. Pylkkanen, B. Mawer, J.A. Kanis, P. Selby, M. Davies, J. Adams, R.M. Francis, 
J. Robinson, and E. McCloskey, Association between vertebral fracture and increased mortality in 
osteoporotic patients. J Bone Miner Res, 2003. 18(7): p. 1254-60. 
39.  Kanis, J.A., A. Oden, O. Johnell, C. De Laet, and B. Jonsson, Excess mortality after hospitalisation for 
vertebral fracture. Osteoporos Int, 2004. 15(2): p. 108-12. 
40.  Oden, A., A. Dawson, W. Dere, O. Johnell, B. Jonsson, and J.A. Kanis, Lifetime risk of hip fractures is 
underestimated. Osteoporos Int, 1998. 8(6): p. 599-603. 
41.  Johnell, O., J.A. Kanis, A. Oden, I. Sernbo, I. Redlund-Johnell, C. Petterson, C. De Laet, and B. 
Jonsson, Mortality after osteoporotic fractures. Osteoporos Int, 2004. 15(1): p. 38-42. 
42.  Parker, M.J. and J.K. Anand, What is the true mortality of hip fractures? Public Health, 1991. 105(6): p. 
443-6. 
43.  Kanis, J.A., A. Oden, O. Johnell, C. De Laet, B. Jonsson, and A.K. Oglesby, The components of excess 
mortality after hip fracture. Bone, 2003. 32(5): p. 468-73. 
44. Kiefer,  N.,  Economic duration data and hazard functions. Journal of Economic Literature, 1998. 26: p. 
646-679. 
45.  Zethraeus, N., F. Borgström, O. Johnell, J. Kanis, and B. Jönsson, Costs and Quality of Life Associated 
with Osteoporosis Related Fractures - Results from a Swedish Survey. Working Paper Series in 
Economics and Finance, 512, 2002. 
46. Lundberg,  L.,  Health-Related Quality of Life in Sweden, in Faculty of Pharmacy. 1999, Uppsala 
University: Uppsala. 
47.  Kanis, J.A., O. Johnell, A. Oden, F. Borgstrom, N. Zethraeus, C. De Laet, and B. Jonsson, The risk and 
burden of vertebral fractures in Sweden. Osteoporos Int, 2004. 15(1): p. 20-6.   22
48.  Jonsson, B., C. Christiansen, O. Johnell, J. Hedbrandt, and G. Karlsson, Cost-effectiveness of fracture 
prevention in established osteoporosis. Scand J Rheumatol Suppl, 1996. 103: p. 30-8. 
49.  Oleksik, A., P. Lips, A. Dawson, M.E. Minshall, W. Shen, C. Cooper, and J. Kanis, Health-related 
quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J 
Bone Miner Res, 2000. 15(7): p. 1384-92. 
50. Johannesson,  M.,  The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics, 
1995. 7(3): p. 242-50. 
51.  Tsevat, J., L. Goldman, J.R. Soukup, G.A. Lamas, K.F. Connors, C.C. Chapin, and T.H. Lee, Stability 
of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making, 1993. 13(2): p. 161-
5. 
52.  Glasziou, P.P., S. Bromwich, and R.J. Simes, Quality of life six months after myocardial infarction 
treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality 
Trial. Med J Aust, 1994. 161(9): p. 532-6. 
53.  Stockholms stads budgetavräkning, in Stadsledningskontorets redovisningsstab. 2003, 
www.stockholm.se. 
54.  Liljegren, G., G. Karlsson, J. Bergh, and L. Holmberg, The cost-effectiveness of routine postoperative 
radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a 
randomized trial. Ann Oncol, 1997. 8(8): p. 757-63. 
55.  Zethraeus, N., L. Stromberg, B. Jonsson, O. Svensson, and G. Ohlen, The cost of a hip fracture. 
Estimates for 1,709 patients in Sweden. Acta Orthop Scand, 1997. 68(1): p. 13-7. 
56.  Ekman, M., N. Zethraeus, U. Dahlstrom, and C. Hoglund, [Cost-effectiveness of bisoprolol in chronic 
heart failure]. Lakartidningen, 2002. 99(7): p. 646-50. 
57.  Col, N.F., G. Weber, A. Stiggelbout, J. Chuo, R. D'Agostino, and P. Corso, Short-term menopausal 
hormone therapy for symptom relief: an updated decision model. Arch Intern Med, 2004. 164(15): p. 
1634-40. 
58. Weinstein,  M.C.,  Estrogen use in postmenopausal women--costs, risks, and benefits. N Engl J Med, 
1980. 303(6): p. 308-16. 
59.  Hornberger, J.C., D.A. Redelmeier, and J. Petersen, Variability among methods to assess patients' well-
being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol, 1992. 45(5): p. 505-12. 
60.  Read, J.L., R.J. Quinn, D.M. Berwick, H.V. Fineberg, and M.C. Weinstein, Preferences for health 
outcomes. Comparison of assessment methods. Med Decis Making, 1984. 4(3): p. 315-29. 
61.  Marshall, D., O. Johnell, and H. Wedel, Meta-analysis of how well measures of bone mineral density 
predict occurrence of osteoporotic fractures. Bmj, 1996. 312(7041): p. 1254-9. 
62.  Klotzbuecher, C.M., P.D. Ross, P.B. Landsman, T.A. Abbott, 3rd, and M. Berger, Patients with prior 
fractures have an increased risk of future fractures: a summary of the literature and statistical 
synthesis. J Bone Miner Res, 2000. 15(4): p. 721-39. 
63.  Zethraeus, N., T. Molin, P. Henriksson, and B. Jonsson, Costs of coronary heart disease and stroke: the 
case of Sweden. J Intern Med, 1999. 246(2): p. 151-9. 
 
   23
FIGURES AND TABLES 
 






Figure 2. Modelling an intervention. 
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Table 1. Life years (LYs) and quality adjusted life years (QALYs) with and without HRT for 
50-60 year-old women with intact uterus or hysterectomised. Discount rate=3%. (Health 
effects undiscounted are shown within parenthesis). 
     Intact uterus  Hysterectomised
50 years  HRT  QALYs  15.99 (24.5)  16.02 (24.57) 
   LYs  20.12 (32.53)  20.15 (32.60) 
 No HRT  QALYs  14.8 (23.25)  14.8 (23.26) 
   LYs  20.14 (32.57)  20.14 (32.59) 
 Diff.  QALYs  1.19 (1.26)  1.22 (1.31) 
   LYs  -0.02 (-0.041)  0.006 (0.014) 
55 years  HRT  QALYs  14.08 (20.52)  14.13 (20.59) 
   LYs  18.35 (28.13)  18.39 (28.20) 
 No HRT  QALYs  12.9 (19.27)  12.9 (19.28) 
   LYs  18.38 (28.16)  18.38 (28.17) 
 Diff.  QALYs  1.18 (1.25)  1.22 (1.31) 
   LYs  -0.02 (-0.04)  0.0089 (0.02) 
60 years  HRT  QALYs  11.95 (16.62)  12.01 (16.71) 
   LYs  16.4 (23.82)  16.47 (23.93) 
 No HRT  QALYs  10.78 (15.38)  10.78 (15.37) 
   LYs  16.43 (23.87)  16.43 (23.86) 
 Diff.  QALYs  1.17 (1.24)  1.24 (1.34) 




Table 2. Costs (SEK, year 2003) with and without HRT for women with intact uterus or 
hysterectomised 50-60 years. Discount rate=3%. 
  Intact Hysterectomised 
  No HRT  HRT  Difference  No HRT  HRT  Difference 
50 years  804 024  819 266  15 242  805 706  815 813  10 107 
55 years  1 312 432  1 325 282  12 850  1 314 143  1 323 882  9 739 
60 years  1 925 364  1 936 097  10 733  1 925 986  1 939 631  13 645 
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Table 3. Cost (SEK) per gained quality adjusted life year (QALY) for women with an intact 
uterus on combination therapy compared with no therapy. 
  50 55 60 
Base case   12 807  10 844  9 159 
      
Sensitivity analysis:     
Excluding cost in added life years  14 494  12 933  13 369 
Discount rates 5%  13 175  11 546  10 071 
Discount rates: 3% costs, 0% effects  12 132  10 249  8 659 
No discounting  11 373  8 900  6 974 
Mild menopausal symptoms  20 907  17 724  15 054 
Severe menopausal symptoms  8 759  7 428  6 277 
No menopausal symptoms  HRT dominated  HRT dominated  HRT dominated 
Treatment duration of 3 years  14 653  12 594  13 537 
No set-time  12 689  11 130  7 103 
10 years set-time  13 372  11 399  10 354 
Population mortality down adjusted 
by 50%  11 577  10 534  8 703 
Intervention costs *1.5  17 337  16 622  14 972 
Reducing utility loss of non-skeletal 
events by half  12 745  10 784  9 098 
No effect of HRT on     
CHD  11 080  9 717  10 991 
Stroke  13 184  9 993  8 967 
VTE  12 644  11 237  11 186 
Colorectal cancer  12 712  10 075  6 766 
Breast cancer  13 298  12 236  11 014 
Fractures  12 518  10 972  4 380 
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Table 4. Cost (SEK) per gained quality adjusted life year (QALY) for hysterectomised 
women on oestrogen only therapy compared with no therapy. 
  50 55 60 
Base case   8 266  7 960  11 043 
      
Sensitivity analysis:     
Excluding cost in added life years  7 532  6 563  5 588 
Discount rates 5%  7 934  7 529  9 543 
Discount rates: 3% costs, 0% effects  7 712  7 413  10 201 
No discounting  9 412  9 557  15 263 
Mild menopausal symptoms  13 274  12 763  17 556 
Severe menopausal symptoms  5 717  5 510  7 677 
No menopausal symptoms  1 510 111  1 000 772  503 160 
Treatment duration of 3 years  9 147  9 946  12 072 
No set-time  8 081  8 330  9 577 
10 years set-time  8 870  8 507  11 078 
Population mortality down adjusted 
by 50%  8 172  7 956  11 388 
Intervention costs *1.5  12 190  11 875  14 896 
Reducing utility loss of non-skeletal 
events by half  8 255  7 949  11 014 
No effect of HRT on     
Stroke  8 569  8 422  10 027 
Fractures  7 900  7 730  9 475 
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APPENDIX - DATA IN THE MODEL 
 
Table A1. Relative risk of hormone replacement therapy. 
Event Estrogen  plus 
progestin 



































Source: [61, 62] 
 
























50  0.63 1.62 4.01  3.13  0.22  0.97  0.62  1.15  0.46  0.72 
55  0.57 1.59 4.40  3.16  0.31  1.37  1.05  1.95  0.65  0.81 
60  1.38 2.45 5.23  3.83  0.57  1.98  1.75  3.11  1.19  1.22 
65  2.64 3.85 6.42  3.97  0.99  3.97  2.79  4.11  1.70  1.66 
70  4.56 6.42 8.19  3.47  1.38  6.62  4.64  5.95  2.27  2.44 
75 10.06  9.78  9.81  3.41  1.57 11.29  7.26 7.50  2.93 3.48 
80  18.17 11.42 11.38 3.35 1.93  17.34  10.26  8.35 2.87  4.67 
85  30.82 14.50 13.15 3.14 2.02  24.16  14.40  9.31 2.23  5.73 
90  46.24 19.28 14.94 1.76 1.52  24.47  14.17  7.89 1.54  4.79 
95  61.66 24.06 16.73 1.76 1.52  24.47  14.17  7.89 1.54  4.79 
100  77.08 28.84 18.52 1.76 1.52  24.47  14.17  7.89 1.54  4.79 
Source:   1. [32]  
  2. Centre for Epidemiology at the National Board of Health and Welfare, Sweden 
 
Table A3. Diagnostic codes used (ICD-10) for extraction from the inpatient register. 
Disease event  ICD-10 
AMI I21 
Coronary insufficiency  I20.0 
Angina pectoris  I20.1,8,9 
Stroke I60-I64 
Deepvein Thrombosis  I80-I82 
Pulmonary embolism  I26 
Breast cancer  C50 
Colorectal cancer  C18.0-9   28
 
Table A4. Normal mortality rates for women in Sweden (per 1000). 
50 2.35 60 5.34 70  13.98  80 47.2 90  158.5 100  347.8 
51 2.33 61 6.25 71  15.88  81  52.28  91  180.1    
52 2.57 62 6.63 72 17.2 82  59.63  92  195.7    
53  2.9  63  7.11  73 19.35 83 66.99 93 212.2    
54 3.12 64 7.56 74  21.76  84  76.62  94  229.4    
55 3.51 65 8.76 75  24.26  85  87.36  95  247.4    
56 4.04 66 9.73 76  27.47  86  100.6  96  266.2    
57  4.39  67 10.24 77 30.86 87 112.9 97 285.6    
58  4.71  68 11.49 78 35.52 88 126.9 98 305.7    
59  5.12  69 12.83 79 40.65 89 142.9 99 326.4    
Source: Statistics Sweden [34] 
 
 
Table A5. Dead 1996 after underlying cause of death. Number of cases. 
  50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89  90- 
All causes of death  897  1029 1415 2318 4141 6399 9175 10419 9414 
Malign tumour in the 
breast  135 130 121 146 177 212 211 166  83 
Malign tumour in the 
colon  37 50 56 85  139  161  165  127 57 
Ischaemic heart disease  56 89  181  423  924  1536  2290  2559  2139 
Cerebrovascular disease  47 54 79  166  417  800  1326  1658  1301 
The share of women dying 
of ischaemic heart disease 
or malign tumour in the 
breast 
0.31 0.31 0.31 0.35 0.40 0.42 0.44 0.43 0.38 
Source: Statistics Sweden, Register for causes of death 1996 [34] 
 
 
Table A6. Normal mortality rates for Swedish women excluding the mortality risk of CHD, 
stroke, breast cancer and colorectal cancer (per 1000). 
50 1.63 60 3.69 70 8.39 80  26.66  90  98.26 100  215.57 
51 1.62 61 4.32 71 9.53 81  29.53  91  111.61   
52 1.78 62 4.58 72  10.32  82  33.69  92  121.32   
53 2.01 63 4.91 73  11.61  83  37.84  93  131.52   
54 2.16 64 5.23 74  13.05  84  43.28  94  142.21   
55 2.41 65 5.66 75  13.99  85  49.55  95  153.37   
56 2.77 66 6.29 76  15.84  86  57.05  96  164.97   
57 3.01 67 6.62 77  17.80  87  64.04  97  177.01   
58 3.23 68 7.43 78  20.48  88  72.02  98  189.46   
59 3.51 69 8.29 79  23.44  89  81.06  99  202.32   
Source: [34] and own calculations 
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Table A7. Risk of mortality the year after hip fracture (per 1000). 
50 31.1 60 42.9 70 73.8 80  150.7  90  293.8 100  375.2 
51 32.1 61 44.3 71 79.3 81  161.5  91  278.1    
52 33.1 62 45.7 72 85.3 82  173.0  92  269.1    
53 34.2 63 47.2 73 91.7 83  185.3  93  281.7    
54 35.3 64 48.8 74 98.5 84  198.3  94  284.0    
55 36.5 65 51.2 75  105.8  85  212.1  95  319.5    
56 37.7 66 55.1 76  113.7  86  226.7  96  318.4    
57 38.9 67 59.3 77  122.0  87  242.2  97  320.1    
58 40.2 68 63.8 78  131.0  88  258.5  98  316.3    




Table A8. Risk of mortality the year after hip fracture adjusted for co-morbidity (per 1000). 
50 11.0 60  16.61  70 31.9 80 78.3 90  199.1 100  356.0 
51 11.3 61  17.67  71 34.9 81 85.0 91  209.5     
52 11.7 62  18.35  72 37.6 82 93.6 92  217.7     
53 12.3 63  19.14  73 41.1 83  102.5  93  233.1     
54 12.8 64  19.93  74 44.8 84  113.1  94  245.8     
55 13.4 65  21.49  75 48.7 85  124.8  95  269.0     
56 14.1 66  23.34  76 53.3 86  138.4  96  281.9     
57 14.7 67  24.96  77 58.2 87  151.7  97  296.0     
58 15.4 68  27.18  78 64.2 88  166.4  98  308.9     





Table A9. Risk of mortality the following years after hip fracture (per 1000). 
50 14.2 60 19.6  70  37.3  80  77.9  90 158.6 100 347.8 
51 14.6 61 20.3  71  40.2  81  83.7  91 180.1    
52 15.1 62 21.1  72  43.3  82  90.0  92 195.7    
53 15.6 63 22.3  73  46.6  83  96.7  93 212.2    
54 16.1 64 23.9  74  50.2  84  103.9  94 229.4    
55 16.7 65 25.7  75  54.0  85  111.5  95 247.4    
56 17.2 66 27.7  76  58.1  86  119.8  96 266.2    
57 17.8 67 29.9  77  62.5  87  128.6  97 285.6    
58 18.4 68 32.2  78  67.3  88  137.9  98 305.7    
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Table A10. Risk of mortality the year after a clinical vertebral fracture (per 1000). 
50 35.0 60 55.1 70 86.8 80  136.6  90  215.1 100  347.8 
51 36.6 61 57.7 71 90.8 81  143.0  91  225.1     
52 38.3 62 60.4 72 95.0 82  149.6  92  235.5     
53 40.1 63 63.2 73 99.4 83  156.6  93  246.5     
54 42.0 64 66.1 74  104.1  84  163.8  94  257.9     
55 43.9 65 69.2 75  108.9  85  171.4  95  269.9     
56 46.0 66 72.4 76  113.9  86  179.4  96  282.4     
57 48.1 67 75.7 77  119.2  87  187.7  97  295.5     
58 50.3 68 79.3 78  124.8  88  196.4  98  309.3     
59 52.7 69 82.9 79  130.6  89  205.6  99  326.4     
Source: [41]  
 
 
Table A11. Risk of mortality the year after a clinical vertebral fracture adjusted for co-
morbidity (per 1000). 
50 12.1 60  20.27  70 35.8 80 74.0 90  175.5 100  347.8 
51 12.6 61  21.68  71 38.4 81 79.5 91  193.6     
52 13.3 62  22.75  72 40.5 82 86.6 92  207.7     
53 14.1 63  23.93  73 43.4 83 93.9 93  222.5     
54 14.8 64  25.12  74 46.4 84  102.8  94  238.0     
55 15.6 65  26.88  75 49.6 85  112.6  95  254.2     
56 16.6 66  28.52  76 53.4 86  124.2  96  271.1     
57 17.5 67  29.89  77 57.4 87  135.4  97  288.6     
58 18.4 68  31.82  78 62.3 88  147.8  98  306.8     
59 19.4 69  33.86  79 67.6 89  161.7  99  326.4     
Calculated: (VertMort-NormMort)*0.3+NormMort 
Source: [41]  
 
 
Table A12. Risk of mortality the following years after a clinical vertebral fracture (per 1000). 
50 23.0 60 36.2 70 57.0 80 89.8 90  158.5 100  347.8 
51 24.1 61 37.9 71 59.7 81 94.0 91  180.1     
52 25.2 62 39.7 72 62.5 82 98.3 92  195.7     
53 26.4 63 41.5 73 65.4 83  102.9  93  212.2     
54 27.6 64 43.4 74 68.4 84  107.7  94  229.4     
55 28.9 65 45.5 75 71.6 85  112.7  95  247.4     
56 30.2 66 47.6 76 74.9 86  117.9  96  266.2     
57 31.6 67 49.8 77 78.4 87  123.4  97  285.6     
58 33.1 68 52.1 78 82.0 88  129.1  98  305.7     
59 34.6 69 54.5 79 85.8 89  142.9  99  326.4     
Source: [41] 
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Table A13. Estimated parameter values in the Weibull survivor and hazard functions. 




AMI Stroke  Angina  Coronary 
insuff 
VTE 
β ˆ   0.043294 0.023651 0.071899  0.067963  0.097074 0.093535  0.051069 
α ˆ   -4.80389 -2.66762 -6.69116  -6.41033 -10.0383 -9.36257 -5.31856 
p ˆ   0.636195 0.628465 0.415446  0.437811  0.866402 0.628174  0.542936 
 
 
Table A14. Risk of mortality the year after breast cancer (per 1000). 
50  68.9  60  104.27  70 156.1 80 230.3 90 332.1 100 463.2 
51  71.9  61  108.62  71 162.5 81 239.2 91 343.9     
52  74.9  62  113.14  72 169.0 82 248.3 92 356.0     
53  78.1  63  117.84  73 175.8 83 257.7 93 368.4     
54  81.4  64  122.72  74 182.8 84 267.5 94 381.1     
55  84.9  65  127.79  75 190.1 85 277.5 95 394.1     
56  88.4  66  133.05  76 197.6 86 287.8 96 407.4     
57  92.2  67  138.51  77 205.4 87 298.4 97 421.0     
58  96.0  68  144.17  78 213.4 88 309.3 98 434.8     
59 100.1 69  150.05  79 221.7 89 320.5 99 448.9     
Source: Centre for Epidemiology at the National Board of Health and Welfare, Sweden 
 
 
Table A15. Risk of mortality the year after colorectal cancer (per 1000). 
50 202.7 60  249.42  70 304.7 80 369.0 90 441.9 100 522.4 
51 207.0 61  254.56  71 310.8 81 375.9 91 449.7     
52 211.4 62  259.78  72 316.9 82 382.9 92 457.5     
53 215.8 63  265.09  73 323.1 83 390.0 93 465.4     
54 220.4 64  270.49  74 329.4 84 397.2 94 473.3     
55 225.0 65  275.98  75 335.7 85 404.4 95 481.3     
56 229.7 66  281.55  76 342.2 86 411.8 96 489.4     
57 234.5 67  287.21  77 348.8 87 419.2 97 497.6     
58 239.4 68  292.96  78 355.4 88 426.7 98 505.8     
59 244.4 69  298.81  79 362.2 89 434.3 99 514.1     
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Table A16. Risk of mortality the year after AMI (per 1000). 
50  44.2  60 88.63 70 173.4 80 323.6 90 551.7 100 807.3 
51  47.4  61 94.92 71 185.1 81 343.0 91 577.7     
52  50.9  62  101.62  72 197.4 82 363.3 92 604.0     
53  54.6  63  108.77  73 210.5 83 384.3 93 630.5     
54  58.5  64  116.39  74 224.3 84 406.2 94 656.9     
55  62.7  65  124.50  75 238.8 85 428.8 95 683.2     
56  67.2  66  133.13  76 254.1 86 452.2 96 709.2     
57  72.1  67  142.32  77 270.3 87 476.2 97 734.8     
58  77.2  68  152.08  78 287.2 88 500.9 98 759.8     
59  82.7  69  162.44  79 305.0 89 526.1 99 784.0     
Source: Centre for Epidemiology at the National Board of Health and Welfare, Sweden 
 
Table A17. Risk of mortality the year after stroke (per 1000). 
50  48.0  60 92.49 70 174.3 80 314.7 90 525.5 100 770.3 
51  51.3  61 98.66 71 185.3 81 332.6 91 549.8     
52  54.8  62  105.22  72 197.0 82 351.3 92 574.3     
53  58.5  63  112.19  73 209.3 83 370.8 93 599.1     
54  62.5  64  119.59  74 222.2 84 391.0 94 624.1     
55  66.8  65  127.44  75 235.8 85 411.8 95 649.1     
56  71.3  66  135.76  76 250.2 86 433.4 96 674.0     
57  76.1  67  144.59  77 265.2 87 455.6 97 698.7     
58  81.2  68  153.93  78 280.9 88 478.4 98 723.1     
59  86.7  69  163.82  79 297.4 89 501.7 99 747.0     
Source: Centre for Epidemiology at the National Board of Health and Welfare, Sweden 
 
 
Table A18. Risk of mortality the year after angina (per 1000). 
50  5.6  60  14.68  70 38.3 80 97.9 90  238.2 100  512.4 
51  6.2  61 16.16 71  42.1  81 107.4 91 259.1     
52  6.8  62 17.80 72  46.3  82 117.6 92 281.4     
53  7.5  63 19.59 73  50.9  83 128.8 93 305.2     
54  8.2  64 21.57 74  55.9  84 141.0 94 330.5     
55  9.1  65 23.74 75  61.5  85 154.2 95 357.3     
56 10.0 66  26.13  76 67.5 86  168.5  96  385.6     
57 11.0 67  28.76  77 74.1 87  184.0  97  415.4     
58 12.1 68  31.64  78 81.4 88  200.7  98  446.5     
59 13.3 69  34.81  79 89.3 89  218.8  99  478.9     
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Table A19. Risk of mortality the year after coronary insufficiency (per 1000). 
50  9.2  60 23.23 70  58.1  80 141.5 90 322.2 100 628.8 
51 10.1 61  25.48  71 63.7 81  154.3  91  347.6     
52 11.1 62  27.94  72 69.7 82  168.1  92  374.3     
53 12.1 63  30.64  73 76.2 83  183.0  93  402.4     
54 13.3 64  33.60  74 83.4 84  199.0  94  431.9     
55 14.6 65  36.83  75 91.2 85  216.2  95  462.5     
56 16.0 66  40.37  76 99.7 86  234.7  96  494.2     
57  17.6  67 44.23 77 108.9 87 254.5 97 526.9     
58  19.3  68 48.46 78 118.9 88 275.7 98 560.4     
59  21.2  69 53.09 79 129.8 89 298.3 99 594.4     
Source: Centre for Epidemiology at the National Board of Health and Welfare, Sweden 
 
 
Table A20. Risk of mortality the year after VTE (per 1000). 
50  61.0  60 99.62 70 160.4 80 252.8 90 384.7 100 554.8 
51  64.1  61  104.55  71 168.1 81 264.1 91 400.1     
52  67.4  62  109.72  72 176.1 82 275.8 92 416.0     
53  70.8  63  115.13  73 184.4 83 288.0 93 432.2     
54  74.3  64  120.78  74 193.1 84 300.5 94 448.8     
55  78.1  65  126.69  75 202.1 85 313.5 95 465.7     
56  82.0  66  132.86  76 211.5 86 326.9 96 483.0     
57  86.1  67  139.32  77 221.2 87 340.7 97 500.6     
58  90.4  68  146.06  78 231.3 88 355.0 98 518.4     
59  94.9  69  153.09  79 241.9 89 369.6 99 536.5     
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Table A21. Quality of life weights in different health states. 
  50-59  60-69 70-79 80-89 
Well
1  0.91  0.87 0.70 0.60 
       
1
st year        
Hip fracture
2  0.72  0.69 0.55 0.48 
Vertebral fracture
2  0.57  0.54 0.44 0.38 
Wrist fracture
2  0.89  0.85 0.68 0.59 
Breast cancer
4  0.81  0.77 0.60 0.50 
Colorectal cancer
4  0.81  0.77 0.60 0.50 
AMI
3  0.81  0.77 0.60 0.50 
Stroke
3  0.81  0.77 0.60 0.50 
Angina
3  0.81  0.77 0.60 0.50 
Coronary insuff
3  0.81  0.77 0.60 0.50 
VTE
4  0.81  0.77 0.60 0.50 
       
2
nd year and following        
Hip fracture
2  0.82  0.78 0.63 0.54 
Vertebral fracture
2   0.85  0.81 0.65 0.56 
Wrist fracture
2  0.91  0.87 0.70 0.60 
Breast cancer
4  0.81  0.77 0.60 0.50 
Colorectal cancer
4  0.81  0.77 0.60 0.50 
AMI 
3  0.81  0.77 0.60 0.50 
Stroke
3  0.81  0.77 0.60 0.50 
Angina
3  0.81  0.77 0.60 0.50 
Coronary insuff
3  0.81  0.77 0.60 0.50 
Source: 1. [45-47] 
             2.  [50] 
             3. [17] 










Table A22. Direct morbidity costs (SEK) in different health states. 
  50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89  90- 
1
st year            
Hip fracture
1  85 748  85 748  85 748  93 353  93 353  164 861  164 861  230 433  230 433 
Vertebral fracture
2   32 504  32 504  32 504  32 504  32 504  32 504  32 504  32 504  32 504 
Wrist fracture
2  20 654  20 654  20 654  20 654  20 654  20 654  20 654  20 654  20 654 
Breast cancer
3  65 156  73 207  64 931  65 287  75 797  65 143  69 373  54 533  54 548 
Colorectal cancer
3  121 825  115 629  124 580  109 985  117 666  112 846  108 490  103 253  100 072 
AMI
4  52 290  52 290  52 290  52 290  52 290  52 290  52 290  52 290  52 290 
Stroke
4  100 682  100 682  100 682  100 682  100 682  100 682  100 682  100 682  100 682 
Angina
4  50 752  50 752  50 752  50 752  50 752  50 752  50 752  50 752  50 752 
Coronary insuff
4  101 964  101 964  101 964  101 964  101 964  101 964  101 964  101 964  101 964 
VTE
3  35 685  35 685  35 685  35 685  35 685  35 685  35 685  35 685  35 685 
           
2
nd year and following            
Hip fracture
5  55 293  55 293  55 293  55 293  55 293  55 293  55 293  55 293  55 293 
Breast cancer
3  6 281  6 281  6 281  6 281  6 281  6 281  6 281  6 281  6 281 
Colorectal cancer
3  27 742  21 066  13 264  11 441  13 825  6 561  2 404  1 037  1 037 
AMI 
4  11 595  11 595  11 595  11 595  11 595  11 595  11 595  11 595  11 595 
Stroke
4  1 655  1 655  1 655  1 655  1 655  1 655  1 655  1 655  1 655 
Angina
4  7 839  7 839  7 839  7 839  7 839  7 839  7 839  7 839  7 839 
Coronary insuff
4  7 839  7 839  7 839  7 839  7 839  7 839  7 839  7 839  7 839 
Source: 1.    [45] 
2. [63]   
3.  Centre for Epidemiology at the National Board of Health and Welfare, Sweden  
4. [53]   
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Table A23. Indirect morbidity costs (SEK) in different health states. 
  50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89  90- 
1
st year            
Hip fracture
  0 0 0 0 0 0 0 0 0 
Vertebral fracture
1   32  352  32  352  32  352  0 0 0 0 0 0 
Wrist fracture
1  3  451  3  451  3  451  0 0 0 0 0 0 
Breast cancer
2  92  953  92  953  92  953  0 0 0 0 0 0 
Colorectal cancer
  0 0 0 0 0 0 0 0 0 
AMI
3 
  100  792  100  792  100  792  0 0 0 0 0 0 
Stroke
3  83  702  83  702  83  702  0 0 0 0 0 0 
Angina
3  100  792  100  792  100  792  0 0 0 0 0 0 
Coronary insuff
3  100  792  100  792  100  792  0 0 0 0 0 0 
VTE  0 0 0 0 0 0 0 0 0 
           
2
nd year and following            
Hip fracture
  0 0 0 0 0 0 0 0 0 
Breast cancer
2    1  568  1  568  1  568  0 0 0 0 0 0 
Colorectal cancer  0 0 0 0 0 0 0 0 0 
AMI
3 
  61  596  61  596  61  596  0 0 0 0 0 0 
Stroke  0 0 0 0 0 0 0 0 0 
Angina
3  61  596  61  596  61  596  0 0 0 0 0 0 
Coronary insuff
3  61  596  61  596  61  596  0 0 0 0 0 0 
Source:   1. [54] 
 2.  [63] 




Table A24. Costs (SEK) in added years of life. 
Age   
50-64  68115 
65-74  -146838 
75-84  -177364 
85-  -265227 
Source: [56] 